SEC Filing · 424B5
Rezolute, Inc.
RZLTNASDAQEQUITYCurrent
SEC Filing
Company context
Inc. Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Regulation FD DisclosureNov 16, 2026
- 424B5 filingNov 16, 2026
- SCHEDULE 13G - filed by PRUDENTIAL FINANCIAL INC regarding Rezolute, Inc.Nov 13, 2026
- Regulation FD Disclosure · Other EventsNov 13, 2026
- FWP - filed by Rezolute, Inc. regarding Rezolute, Inc.Nov 13, 2026
As-filed source
As filedOpen full document ↗